These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25921239)

  • 1. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
    Lin JA; He P
    Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to special issue on biomarker-based clinical trial designs in oncology.
    Sargent DJ; Mandrekar S; Grothey A
    Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
    Simon R
    Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker.
    Beckman RA; Antonijevic Z; Kalamegham R; Chen C
    Clin Pharmacol Ther; 2016 Dec; 100(6):617-625. PubMed ID: 27509351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the design and conduct of the BATTLE trials.
    Liu S; Lee JJ
    Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
    Galanis E; Wu W; Sarkaria J; Chang SM; Colman H; Sargent D; Reardon DA
    Curr Oncol Rep; 2011 Feb; 13(1):42-9. PubMed ID: 21125354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial designs incorporating predictive biomarkers.
    Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
    Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating biomarkers in colorectal cancer trials in the West and China.
    Tejpar S; Shen L; Wang X; Schilsky RL
    Nat Rev Clin Oncol; 2015 Sep; 12(9):553-60. PubMed ID: 25963094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.